You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Harvard Business School
Medtronic
AstraZeneca
Mallinckrodt

Last Updated: February 26, 2024

Abametapir - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for abametapir and what is the scope of freedom to operate?

Abametapir is the generic ingredient in one branded drug marketed by Hatchtech and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abametapir has thirty-five patent family members in fifteen countries.

One supplier is listed for this compound.

Summary for abametapir
International Patents:35
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 112
Clinical Trials: 6
Patent Applications: 489
What excipients (inactive ingredients) are in abametapir?abametapir excipients list
DailyMed Link:abametapir at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for abametapir
Generic Entry Date for abametapir*:
Constraining patent/regulatory exclusivity:
Dosage:
LOTION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for abametapir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hatchtech Pty LtdPhase 2
Dr. Reddy's Laboratories LimitedPhase 2
Dr. Reddy's Laboratories LimitedPhase 3

See all abametapir clinical trials

US Patents and Regulatory Information for abametapir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hatchtech XEGLYZE abametapir LOTION;TOPICAL 206966-001 Jul 24, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Hatchtech XEGLYZE abametapir LOTION;TOPICAL 206966-001 Jul 24, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Hatchtech XEGLYZE abametapir LOTION;TOPICAL 206966-001 Jul 24, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hatchtech XEGLYZE abametapir LOTION;TOPICAL 206966-001 Jul 24, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Hatchtech XEGLYZE abametapir LOTION;TOPICAL 206966-001 Jul 24, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for abametapir

Country Patent Number Title Estimated Expiration
Portugal 2457582 ⤷  Try a Trial
South Africa 200706806 Methods and compositions for controlling ectoparasites ⤷  Try a Trial
China 1822854 Methods and compositions for controlling ectoparasites ⤷  Try a Trial
Brazil PI0606577 métodos de tratamento ou prevenção de infestação de ectoparasitas em hospedeiro de planta e de inibição da eclosão de ovo de ectoparasita ⤷  Try a Trial
New Zealand 720995 Pediculicidal composition ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKinsey
Mallinckrodt
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.